T. Juhl

Beneficial impact of spironolactone in diabetic nephropathy.

H. Parving, L. Tarnow, K. Rossing, 2005, Kidney international.

Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

H. Parving, F. Cambien, L. Tarnow, 2003, Diabetes care.

Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

H. Parving, F. Cambien, L. Tarnow, 2002, Kidney international.

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.

H. Parving, L. Tarnow, C. Stehouwer, 2008, Kidney international.

Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria

H. Parving, C. Stehouwer, C. Schalkwijk, 2009, Diabetes Care.

Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.

H. Parving, L. Tarnow, P. Rossing, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Optimal dose of losartan for renoprotection in diabetic nephropathy.

H. Parving, P. Rossing, S. Andersen, 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial

H. Parving, C. Stehouwer, C. Schalkwijk, 2010, Diabetologia.

Paternal depression in the postnatal period assessed with traditional and male depression scales

T. Juhl, S. A. Madsen, 2007 .

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.

F Boomsma, H. Parving, L. Tarnow, 2006, Kidney international.

Co-workers in the research program :

T. Juhl, 2017 .